Full-Time

Engineering Governance Manager

Project Controls

Updated on 9/3/2026

Integra LifeSciences

Integra LifeSciences

1,001-5,000 employees

Regenerative medicine, surgical devices provider

Compensation Overview

$109.3k - $149.5k/yr

+ Bonus + Commission + Equity

Princeton, NJ, USA

In Person

Travel domestically and internationally across company locations is required.

Bachelor's

Category
Project & Program Management (1)
Required Skills
CAD
Microsoft Office
Forecasting
Risk Management

Get referred to Integra LifeSciences

See people who can refer or advise you

Requirements
  • A bachelor's degree in an engineering discipline, such as Mechanical Engineering or Electrical Engineering, or equivalent.
  • At least 10 years of experience in engineering, preferably within medical device companies or regulated environments.
  • Three to five years of project management experience in engineering or manufacturing environments, with working knowledge of Engineering Change Controls, ISO, Quality System Regulation, and design control procedures.
  • Demonstrated experience with project controls including scope, cost, schedule, forecasting, risk, and change management.
  • Working knowledge of engineering change control, quality management systems, QMSR, and applicable design and change-control requirements.
  • Experience developing or implementing engineering standards, procedures, governance processes, or project execution methodologies.
  • Experience with engineering documentation, drawing management, document-control systems, and project turnover requirements.
  • Experience working with architectural, engineering, construction, commissioning, and other external technical service providers.
  • Demonstrated ability to manage multiple projects and priorities simultaneously across geographically dispersed locations.
  • Experience leading cross-functional teams and communicating or presenting to senior leadership.
  • Strong understanding of engineering documentation and facility and equipment lifecycle documentation.
  • Working knowledge of CAD systems and engineering drawing-management practices.
  • Strong analytical, organizational, problem-solving, and communication skills.
  • Ability to develop processes and standards that are practical, scalable, and appropriate for global deployment.
  • Ability to influence teams and drive standardization across a matrixed organization without direct reporting authority.
  • Proficiency in Microsoft Office and applicable project management, project controls, CAD, and document-management systems.
  • Familiarity with environmental, health, and safety requirements applicable to construction and engineering activities.
  • Ability to work independently while collaborating across all levels of the organization.
  • Ability to travel domestically and internationally via car, train, or airplane as required.
  • Ability to periodically lift or move items up to twenty-five pounds.
  • Ability to work in environments with potential exposure to flammable and corrosive liquids, compressed gases, high-temperature steam and water systems, construction equipment, and medical waste, using required personal protective equipment.
Responsibilities
  • Maintain global engineering governance standards, procedures, tools, and templates for capital project execution.
  • Manage standardized project controls for scope, cost, schedule, risk, forecasting, change management, and performance reporting.
  • Implement a consistent capital project stage-gate process from project initiation through design, execution, commissioning, turnover, and closeout.
  • Provide technical and governance leadership for multidisciplinary engineering, construction, and project lifecycle activities.
  • Serve as a primary interface between Integra and external engineering, architectural, construction, and technical service providers.
  • Lead global documentation efforts for facility engineering, construction, commissioning, validation, and project lifecycle activities.
  • Establish and maintain global engineering documentation and CAD standards, including document structure, naming, revision control, storage, retention, and project turnover requirements.
  • Partner with Quality, EHS&S, Procurement, Finance, IT, and site teams to ensure engineering projects meet applicable business, regulatory, and operational requirements.
  • Evaluate and implement technology solutions, including technical drawing databases and engineering administration platforms, to improve document management, data integrity, and operational efficiency.
  • Support development and administration of the Integra Facilities Management System, including engineering standards, SOPs, work instructions, forms, and templates.
  • Provide project and portfolio reporting, identify systemic gaps, and drive continuous improvement and global standardization across Facilities and Engineering.
Desired Qualifications
  • Experience in medical device companies or regulated environments.

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 2.4% to $391.9 million, beating expectations.
  • Adjusted EPS jumped to $0.54, and full-year guidance rose to $2.40-$2.50.
  • April 15, 2026 arbitration victory removed ACell earnout liability and reduced legal overhang.

What critics are saying

  • FDA warning letters and the 2025 Boston recall keep disrupting Integra’s core tissue business.
  • The 2026 MediHoney recall and 65 Princeton layoffs signal continuing quality failures and restructuring.
  • If Braintree ramps slowly, SurgiMend delays and Class II recalls can permanently cede share.

What makes Integra LifeSciences unique

  • Integra owns neurosurgery, tissue reconstruction, and ENT niches with specialized device portfolios.
  • Its Braintree, Massachusetts facility restarts SurgiMend production after Boston recall fallout.
  • Stuart Essig returned as CEO in May 2026, tightening execution around remediation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.

Yahoo Finance
May 15th, 2026
Integra LifeSciences beats Q1 expectations, raises full-year EPS guidance to $2.45

Integra LifeSciences reported first-quarter results that beat Wall Street expectations, with revenue of $391.9 million and adjusted EPS of $0.54, surpassing estimates by 2.6% and 33.4%, respectively. The medical device company attributed the performance to stronger tissue reconstruction demand, improved supply execution and operational improvements. CEO Stuart Essig emphasised that quality remediation and operational work enabled more reliable product availability. CFO Lea Knight said increased gross margins were driven by favourable product mix, tariff benefits and reduced remediation costs. The company reaffirmed its full-year revenue guidance of $1.68 billion whilst raising adjusted EPS guidance to $2.45, a 4.3% increase. Operating margin improved to 10.4% from 8.2% year-on-year. Management indicated no plans for divestitures, focusing instead on current product mix and gradual market share recovery.

Yahoo Finance
May 5th, 2026
Integra LifeSciences beats Q1 guidance, raises EPS outlook on tariff gains

Integra LifeSciences reported first-quarter results exceeding guidance, with revenue of $392 million and adjusted earnings per share of $0.54. Revenue increased 2.4% on a reported basis and 1.3% organically, driven by product demand and supply improvements. The company announced leadership changes, with Chairman Stuart Essig resuming the role of President and CEO following Mojdeh Poul's departure. Essig said the decision was mutual and cited differences in strategic topics, though transformation initiatives will continue. Mike McBreen was appointed as the company's first Chief Commercial Officer to elevate commercial priorities. Integra raised its full-year adjusted EPS guidance by $0.10, primarily due to favourable tariff outcomes in the first quarter. CFO Lea Knight noted a $0.02 net tariff benefit but said future tariff assumptions remain uncertain.

Associated Press
May 5th, 2026
Integra LifeSciences Q1 revenues rise 2.4% to $391.9M, raises full-year EPS guidance

Integra LifeSciences reported first quarter 2026 revenues of $391.9 million, up 2.4% on a reported basis and 1.3% organically compared to the prior year. The medical technology company posted adjusted earnings per diluted share of $0.54, up from $0.41 in the prior year. The company reaffirmed full-year 2026 revenue guidance of $1.662 billion to $1.702 billion whilst raising its adjusted earnings per share guidance to $2.40 to $2.50, up from the previous range of $2.30 to $2.40. Adjusted EBITDA for the quarter was $76.2 million, representing 19.4% of revenue, compared to $63.6 million or 16.6% in the prior year. The company generated $9.8 million in operating cash flow during the quarter, with net debt standing at $1.6 billion.